Stem definition | Drug id | CAS RN |
---|---|---|
tyrosine kinase inhibitors | 1548 | 231277-92-2 |
Dose | Unit | Route |
---|---|---|
1.25 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 30.73 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
June 10, 2008 | EMA | ||
March 13, 2007 | FDA | NOVARTIS PHARMS CORP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Palmar-plantar erythrodysaesthesia syndrome | 1776.19 | 20.05 | 563 | 22311 | 19535 | 50562715 |
Diarrhoea | 1457.85 | 20.05 | 1535 | 21339 | 586941 | 49995309 |
Disease progression | 778.19 | 20.05 | 503 | 22371 | 95363 | 50486887 |
Metastases to central nervous system | 595.48 | 20.05 | 215 | 22659 | 11067 | 50571183 |
Malignant neoplasm progression | 359.21 | 20.05 | 275 | 22599 | 67849 | 50514401 |
Neutropenia | 297.90 | 20.05 | 350 | 22524 | 147615 | 50434635 |
Paronychia | 282.63 | 20.05 | 98 | 22776 | 4466 | 50577784 |
Metastases to liver | 257.83 | 20.05 | 142 | 22732 | 19962 | 50562288 |
Metastases to lung | 251.26 | 20.05 | 115 | 22759 | 10905 | 50571345 |
Dehydration | 232.45 | 20.05 | 314 | 22560 | 152135 | 50430115 |
Metastases to bone | 190.09 | 20.05 | 112 | 22762 | 17883 | 50564367 |
Ejection fraction decreased | 187.10 | 20.05 | 112 | 22762 | 18408 | 50563842 |
Skin toxicity | 185.67 | 20.05 | 69 | 22805 | 3844 | 50578406 |
Vomiting | 176.56 | 20.05 | 531 | 22343 | 460227 | 50122023 |
Breast cancer metastatic | 169.10 | 20.05 | 86 | 22788 | 10278 | 50571972 |
Blood bilirubin increased | 161.34 | 20.05 | 126 | 22748 | 31912 | 50550338 |
Metastases to lymph nodes | 149.80 | 20.05 | 70 | 22804 | 6954 | 50575296 |
Skin fissures | 141.62 | 20.05 | 72 | 22802 | 8596 | 50573654 |
Death | 134.79 | 20.05 | 386 | 22488 | 324993 | 50257257 |
Mucosal inflammation | 126.96 | 20.05 | 121 | 22753 | 40021 | 50542229 |
Gastrointestinal toxicity | 126.41 | 20.05 | 55 | 22819 | 4622 | 50577628 |
Jaundice | 120.36 | 20.05 | 98 | 22776 | 26331 | 50555919 |
Metastases to skin | 110.57 | 20.05 | 36 | 22838 | 1347 | 50580903 |
Dry skin | 108.66 | 20.05 | 115 | 22759 | 43076 | 50539174 |
Stomatitis | 107.08 | 20.05 | 176 | 22698 | 101168 | 50481082 |
Rash | 104.55 | 20.05 | 432 | 22442 | 437039 | 50145211 |
Hypokalaemia | 104.21 | 20.05 | 161 | 22713 | 87831 | 50494419 |
Hepatic function abnormal | 100.47 | 20.05 | 97 | 22777 | 32584 | 50549666 |
Nausea | 89.23 | 20.05 | 583 | 22291 | 704815 | 49877435 |
Febrile neutropenia | 86.62 | 20.05 | 157 | 22717 | 97510 | 50484740 |
Lymphangiosis carcinomatosa | 83.08 | 20.05 | 28 | 22846 | 1168 | 50581082 |
Hepatotoxicity | 78.44 | 20.05 | 78 | 22796 | 27148 | 50555102 |
Pyrexia | 77.35 | 20.05 | 358 | 22516 | 379845 | 50202405 |
Haematotoxicity | 75.21 | 20.05 | 46 | 22828 | 7849 | 50574401 |
Decreased appetite | 73.10 | 20.05 | 228 | 22646 | 200695 | 50381555 |
Alanine aminotransferase increased | 72.02 | 20.05 | 137 | 22737 | 88222 | 50494028 |
Drug hypersensitivity | 70.38 | 20.05 | 14 | 22860 | 250996 | 50331254 |
Cardiotoxicity | 69.65 | 20.05 | 42 | 22832 | 6985 | 50575265 |
Hyperbilirubinaemia | 67.11 | 20.05 | 46 | 22828 | 9524 | 50572726 |
Drug ineffective | 62.75 | 20.05 | 178 | 22696 | 819155 | 49763095 |
Weight increased | 61.56 | 20.05 | 9 | 22865 | 201882 | 50380368 |
Condition aggravated | 61.07 | 20.05 | 29 | 22845 | 297029 | 50285221 |
Joint swelling | 56.80 | 20.05 | 20 | 22854 | 245266 | 50336984 |
Arthralgia | 54.73 | 20.05 | 71 | 22803 | 438631 | 50143619 |
Pleural effusion | 54.08 | 20.05 | 116 | 22758 | 81338 | 50500912 |
Fall | 53.28 | 20.05 | 44 | 22830 | 334888 | 50247362 |
Dermatitis acneiform | 52.92 | 20.05 | 29 | 22845 | 4028 | 50578222 |
Therapeutic product effect decreased | 49.51 | 20.05 | 3 | 22871 | 136047 | 50446203 |
Completed suicide | 47.72 | 20.05 | 3 | 22871 | 131886 | 50450364 |
Skin exfoliation | 47.67 | 20.05 | 67 | 22807 | 33545 | 50548705 |
Maternal exposure during pregnancy | 46.71 | 20.05 | 8 | 22866 | 159770 | 50422480 |
Neoplasm progression | 45.70 | 20.05 | 61 | 22813 | 29096 | 50553154 |
Off label use | 44.07 | 20.05 | 93 | 22781 | 474333 | 50107917 |
Superior vena cava syndrome | 41.26 | 20.05 | 14 | 22860 | 596 | 50581654 |
Breast cancer | 40.61 | 20.05 | 71 | 22803 | 42819 | 50539431 |
Neurotoxicity | 40.19 | 20.05 | 41 | 22833 | 14699 | 50567551 |
Asthenia | 40.16 | 20.05 | 264 | 22610 | 318778 | 50263472 |
Biliary dilatation | 40.06 | 20.05 | 19 | 22855 | 1950 | 50580300 |
Aspartate aminotransferase increased | 39.60 | 20.05 | 100 | 22774 | 77898 | 50504352 |
Cellulitis | 39.37 | 20.05 | 94 | 22780 | 70704 | 50511546 |
Neoplasm | 38.07 | 20.05 | 27 | 22847 | 5901 | 50576349 |
Metastasis | 37.90 | 20.05 | 24 | 22850 | 4351 | 50577899 |
Product dose omission issue | 37.66 | 20.05 | 18 | 22856 | 183820 | 50398430 |
Onychalgia | 37.64 | 20.05 | 14 | 22860 | 781 | 50581469 |
Sinusitis | 37.62 | 20.05 | 15 | 22859 | 170543 | 50411707 |
Leukopenia | 36.84 | 20.05 | 89 | 22785 | 67439 | 50514811 |
Glossodynia | 35.56 | 20.05 | 5 | 22869 | 115564 | 50466686 |
Pain | 35.07 | 20.05 | 139 | 22735 | 578764 | 50003486 |
Neuropathy peripheral | 34.37 | 20.05 | 109 | 22765 | 96648 | 50485602 |
Second primary malignancy | 34.36 | 20.05 | 27 | 22847 | 6887 | 50575363 |
Transaminases | 34.12 | 20.05 | 8 | 22866 | 84 | 50582166 |
Nail disorder | 34.01 | 20.05 | 31 | 22843 | 9677 | 50572573 |
Ascites | 33.47 | 20.05 | 59 | 22815 | 35802 | 50546448 |
Limbal stem cell deficiency | 33.30 | 20.05 | 6 | 22868 | 13 | 50582237 |
Hypertension | 33.22 | 20.05 | 28 | 22846 | 211175 | 50371075 |
Feeling abnormal | 33.11 | 20.05 | 8 | 22866 | 125484 | 50456766 |
Thrombocytopenia | 32.59 | 20.05 | 129 | 22745 | 127544 | 50454706 |
Musculoskeletal stiffness | 32.35 | 20.05 | 9 | 22865 | 128472 | 50453778 |
Radiation necrosis | 31.82 | 20.05 | 10 | 22864 | 333 | 50581917 |
Metastatic neoplasm | 31.04 | 20.05 | 20 | 22854 | 3734 | 50578516 |
Drug interaction | 30.74 | 20.05 | 27 | 22847 | 199594 | 50382656 |
Onycholysis | 30.70 | 20.05 | 14 | 22860 | 1314 | 50580936 |
Therapeutic product effect incomplete | 30.53 | 20.05 | 3 | 22871 | 91512 | 50490738 |
Recurrent cancer | 29.88 | 20.05 | 15 | 22859 | 1742 | 50580508 |
Metastases to spine | 28.26 | 20.05 | 17 | 22857 | 2814 | 50579436 |
Left ventricular dysfunction | 28.23 | 20.05 | 29 | 22845 | 10477 | 50571773 |
Tumour marker increased | 28.21 | 20.05 | 19 | 22855 | 3821 | 50578429 |
Nail infection | 28.18 | 20.05 | 15 | 22859 | 1966 | 50580284 |
Pericardial effusion | 27.73 | 20.05 | 45 | 22829 | 25544 | 50556706 |
Breast neoplasm | 27.72 | 20.05 | 13 | 22861 | 1300 | 50580950 |
Injection site pain | 27.53 | 20.05 | 8 | 22866 | 111016 | 50471234 |
Radiation pneumonitis | 27.52 | 20.05 | 13 | 22861 | 1322 | 50580928 |
Neoplasm malignant | 27.48 | 20.05 | 43 | 22831 | 23672 | 50558578 |
Plantar erythema | 27.10 | 20.05 | 8 | 22866 | 215 | 50582035 |
Erythema | 26.81 | 20.05 | 134 | 22740 | 146280 | 50435970 |
Performance status decreased | 26.37 | 20.05 | 17 | 22857 | 3178 | 50579072 |
Exposure during pregnancy | 26.10 | 20.05 | 11 | 22863 | 121004 | 50461246 |
Infusion related reaction | 26.02 | 20.05 | 23 | 22851 | 169534 | 50412716 |
Brain oedema | 26.00 | 20.05 | 30 | 22844 | 12340 | 50569910 |
Breast cancer recurrent | 25.98 | 20.05 | 18 | 22856 | 3790 | 50578460 |
Wound | 25.55 | 20.05 | 8 | 22866 | 105786 | 50476464 |
Swelling | 25.50 | 20.05 | 32 | 22842 | 200840 | 50381410 |
Discomfort | 24.78 | 20.05 | 9 | 22865 | 108371 | 50473879 |
Botryomycosis | 24.40 | 20.05 | 5 | 22869 | 26 | 50582224 |
Arthritis | 23.93 | 20.05 | 5 | 22869 | 86716 | 50495534 |
Anal erythema | 23.93 | 20.05 | 7 | 22867 | 182 | 50582068 |
Dyschezia | 23.82 | 20.05 | 13 | 22861 | 1791 | 50580459 |
Skin mass | 23.27 | 20.05 | 19 | 22855 | 5116 | 50577134 |
Neoplasm recurrence | 23.06 | 20.05 | 14 | 22860 | 2355 | 50579895 |
Ingrowing nail | 22.98 | 20.05 | 13 | 22861 | 1919 | 50580331 |
Asthma | 22.97 | 20.05 | 6 | 22868 | 89331 | 50492919 |
Alopecia | 22.71 | 20.05 | 48 | 22826 | 244999 | 50337251 |
Abdominal pain | 21.96 | 20.05 | 182 | 22692 | 236046 | 50346204 |
Anxiety | 21.81 | 20.05 | 29 | 22845 | 177577 | 50404673 |
Central nervous system lesion | 21.63 | 20.05 | 24 | 22850 | 9465 | 50572785 |
Brain neoplasm | 21.53 | 20.05 | 16 | 22858 | 3757 | 50578493 |
Contusion | 21.45 | 20.05 | 12 | 22862 | 112171 | 50470079 |
Bone cancer metastatic | 21.38 | 20.05 | 6 | 22868 | 134 | 50582116 |
Disease recurrence | 21.33 | 20.05 | 35 | 22839 | 20046 | 50562204 |
Jaundice cholestatic | 21.27 | 20.05 | 18 | 22856 | 5093 | 50577157 |
Psoriasis | 21.18 | 20.05 | 3 | 22871 | 68997 | 50513253 |
Hyperhidrosis | 21.17 | 20.05 | 7 | 22867 | 89419 | 50492831 |
General physical health deterioration | 21.08 | 20.05 | 123 | 22751 | 142311 | 50439939 |
Hormone receptor positive breast cancer | 20.98 | 20.05 | 8 | 22866 | 478 | 50581772 |
Malignant pleural effusion | 20.73 | 20.05 | 13 | 22861 | 2317 | 50579933 |
Abdominal discomfort | 20.13 | 20.05 | 47 | 22827 | 231594 | 50350656 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Duodenal ulcer perforation | 52.66 | 33.86 | 12 | 1076 | 1494 | 29571945 |
Diarrhoea | 43.87 | 33.86 | 57 | 1031 | 332641 | 29240798 |
Metastases to lung | 36.85 | 33.86 | 13 | 1075 | 7842 | 29565597 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Palmar-plantar erythrodysaesthesia syndrome | 1116.28 | 20.04 | 371 | 15167 | 28448 | 64454746 |
Diarrhoea | 1014.11 | 20.04 | 1038 | 14500 | 721666 | 63761528 |
Disease progression | 497.38 | 20.04 | 348 | 15190 | 141332 | 64341862 |
Metastases to central nervous system | 367.86 | 20.04 | 135 | 15403 | 13777 | 64469417 |
Malignant neoplasm progression | 270.46 | 20.04 | 221 | 15317 | 112650 | 64370544 |
Metastases to lung | 237.59 | 20.04 | 101 | 15437 | 15163 | 64468031 |
Metastases to liver | 197.09 | 20.04 | 102 | 15436 | 23839 | 64459355 |
Dehydration | 167.25 | 20.04 | 232 | 15306 | 216531 | 64266663 |
Breast cancer metastatic | 161.85 | 20.04 | 62 | 15476 | 7107 | 64476087 |
Paronychia | 160.50 | 20.04 | 60 | 15478 | 6432 | 64476762 |
Metastases to bone | 150.96 | 20.04 | 81 | 15457 | 20354 | 64462840 |
Vomiting | 140.71 | 20.04 | 367 | 15171 | 550750 | 63932444 |
Ejection fraction decreased | 135.37 | 20.04 | 85 | 15453 | 28622 | 64454572 |
Gastrointestinal toxicity | 134.54 | 20.04 | 50 | 15488 | 5272 | 64477922 |
Metastases to lymph nodes | 123.53 | 20.04 | 54 | 15484 | 8663 | 64474531 |
Metastases to skin | 122.00 | 20.04 | 34 | 15504 | 1418 | 64481776 |
Neutropenia | 104.41 | 20.04 | 198 | 15340 | 239426 | 64243768 |
Skin toxicity | 100.43 | 20.04 | 43 | 15495 | 6559 | 64476635 |
Skin fissures | 96.72 | 20.04 | 48 | 15490 | 10258 | 64472936 |
Mucosal inflammation | 86.06 | 20.04 | 90 | 15448 | 62494 | 64420700 |
Death | 81.43 | 20.04 | 278 | 15260 | 482427 | 64000767 |
Nausea | 80.32 | 20.04 | 387 | 15151 | 785413 | 63697781 |
Blood bilirubin increased | 74.22 | 20.04 | 80 | 15458 | 57473 | 64425721 |
Hypokalaemia | 72.96 | 20.04 | 116 | 15422 | 121787 | 64361407 |
Rash | 71.17 | 20.04 | 257 | 15281 | 458292 | 64024902 |
Hepatotoxicity | 68.86 | 20.04 | 65 | 15473 | 39897 | 64443297 |
Lymphangiosis carcinomatosa | 68.52 | 20.04 | 23 | 15515 | 1798 | 64481396 |
Jaundice | 67.10 | 20.04 | 70 | 15468 | 48442 | 64434752 |
Cardiotoxicity | 62.89 | 20.04 | 36 | 15502 | 10238 | 64472956 |
Haematotoxicity | 62.82 | 20.04 | 39 | 15499 | 12857 | 64470337 |
Dry skin | 60.56 | 20.04 | 68 | 15470 | 51093 | 64432101 |
Stomatitis | 59.74 | 20.04 | 100 | 15438 | 109505 | 64373689 |
Hyperbilirubinaemia | 51.64 | 20.04 | 42 | 15496 | 21163 | 64462031 |
Asthenia | 41.42 | 20.04 | 208 | 15330 | 427836 | 64055358 |
Condition aggravated | 41.39 | 20.04 | 19 | 15519 | 372407 | 64110787 |
Dermatitis acneiform | 39.77 | 20.04 | 25 | 15513 | 8418 | 64474776 |
Onycholysis | 36.47 | 20.04 | 14 | 15524 | 1612 | 64481582 |
Decreased appetite | 36.38 | 20.04 | 149 | 15389 | 281140 | 64202054 |
Biliary dilatation | 35.24 | 20.04 | 15 | 15523 | 2253 | 64480941 |
Tumour marker increased | 35.15 | 20.04 | 17 | 15521 | 3433 | 64479761 |
Drug interaction | 35.06 | 20.04 | 22 | 15516 | 362061 | 64121133 |
Metastases to spine | 34.27 | 20.04 | 17 | 15521 | 3626 | 64479568 |
Transaminases | 34.03 | 20.04 | 7 | 15531 | 76 | 64483118 |
Onychalgia | 33.73 | 20.04 | 11 | 15527 | 786 | 64482408 |
Drug hypersensitivity | 33.62 | 20.04 | 8 | 15530 | 237807 | 64245387 |
Fall | 33.14 | 20.04 | 31 | 15507 | 416795 | 64066399 |
Limbal stem cell deficiency | 32.62 | 20.04 | 6 | 15532 | 34 | 64483160 |
Abdominal pain | 31.73 | 20.04 | 154 | 15384 | 312221 | 64170973 |
Weight increased | 30.50 | 20.04 | 7 | 15531 | 213341 | 64269853 |
Hepatic function abnormal | 30.23 | 20.04 | 55 | 15483 | 64258 | 64418936 |
Hormone receptor positive breast cancer | 29.27 | 20.04 | 8 | 15530 | 310 | 64482884 |
Second primary malignancy | 29.12 | 20.04 | 24 | 15514 | 12313 | 64470881 |
Neoplasm progression | 27.29 | 20.04 | 41 | 15497 | 40923 | 64442271 |
Metastasis | 27.17 | 20.04 | 17 | 15521 | 5678 | 64477516 |
Breast cancer recurrent | 27.14 | 20.04 | 13 | 15525 | 2570 | 64480624 |
Neurotoxicity | 26.73 | 20.04 | 33 | 15505 | 27371 | 64455823 |
Disease recurrence | 26.11 | 20.04 | 35 | 15503 | 31475 | 64451719 |
Osteonecrosis of jaw | 25.32 | 20.04 | 39 | 15499 | 39786 | 64443408 |
Metastases to the mediastinum | 25.17 | 20.04 | 8 | 15530 | 526 | 64482668 |
Recurrent cancer | 25.11 | 20.04 | 12 | 15526 | 2361 | 64480833 |
Pyrexia | 24.97 | 20.04 | 224 | 15314 | 558420 | 63924774 |
Botryomycosis | 23.93 | 20.04 | 5 | 15533 | 59 | 64483135 |
Cholangitis | 23.40 | 20.04 | 20 | 15518 | 10782 | 64472412 |
Pleural effusion | 23.06 | 20.04 | 75 | 15463 | 126484 | 64356710 |
Pericardial effusion | 22.96 | 20.04 | 37 | 15501 | 39217 | 64443977 |
Left ventricular dysfunction | 22.60 | 20.04 | 24 | 15514 | 16930 | 64466264 |
Hypertension | 22.13 | 20.04 | 18 | 15520 | 259243 | 64223951 |
Breast cancer | 22.07 | 20.04 | 31 | 15507 | 29117 | 64454077 |
Arthralgia | 22.03 | 20.04 | 46 | 15492 | 442214 | 64040980 |
Neoplasm | 21.63 | 20.04 | 16 | 15522 | 7015 | 64476179 |
Skin mass | 21.48 | 20.04 | 16 | 15522 | 7090 | 64476104 |
Cellulitis | 21.29 | 20.04 | 60 | 15478 | 93597 | 64389597 |
Radiation pneumonitis | 21.28 | 20.04 | 12 | 15526 | 3316 | 64479878 |
Joint swelling | 20.94 | 20.04 | 13 | 15525 | 215369 | 64267825 |
Nail disorder | 20.82 | 20.04 | 17 | 15521 | 8607 | 64474587 |
Plantar erythema | 20.69 | 20.04 | 6 | 15532 | 289 | 64482905 |
Performance status decreased | 20.66 | 20.04 | 14 | 15524 | 5350 | 64477844 |
Gastric neoplasm | 20.55 | 20.04 | 6 | 15532 | 296 | 64482898 |
Metastatic neoplasm | 20.54 | 20.04 | 13 | 15525 | 4429 | 64478765 |
Onychoclasis | 20.14 | 20.04 | 13 | 15525 | 4579 | 64478615 |
None
Source | Code | Description |
---|---|---|
ATC | L01EH01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS PROTEIN KINASE INHIBITORS Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors |
FDA MoA | N0000175076 | Protein Kinase Inhibitors |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D047428 | Protein Kinase Inhibitors |
FDA EPC | N0000175605 | Kinase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
HER2-positive carcinoma of breast | indication | 427685000 | |
Torsades de pointes | contraindication | 31722008 | |
Hypokalemia | contraindication | 43339004 | |
Hepatic failure | contraindication | 59927004 | |
Interstitial pneumonia | contraindication | 64667001 | |
Left heart failure | contraindication | 85232009 | |
Prolonged QT interval | contraindication | 111975006 | |
Liver function tests abnormal | contraindication | 166603001 | |
Hypomagnesemia | contraindication | 190855004 | |
Drug-induced hepatitis | contraindication | 235876009 | |
Pregnancy, function | contraindication | 289908002 | |
Severe diarrhea | contraindication | 409587002 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Congenital long QT syndrome | contraindication | 442917000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 5.62 | Basic |
pKa2 | 4.99 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Epidermal growth factor receptor | Kinase | INHIBITOR | Kd | 9.04 | CHEMBL | CHEMBL | |||
Receptor tyrosine-protein kinase erbB-2 | Kinase | INHIBITOR | Kd | 8.15 | CHEMBL | CHEMBL | |||
Platelet-derived growth factor receptor beta | Kinase | IC50 | 5.07 | CHEMBL | |||||
Tyrosine-protein kinase ABL1 | Kinase | IC50 | 4.64 | CHEMBL | |||||
Solute carrier organic anion transporter family member 1B1 | Transporter | WOMBAT-PK | |||||||
Cyclin-dependent kinase 2 | Kinase | IC50 | 4.96 | CHEMBL | |||||
Insulin receptor | Kinase | AGONIST | IC50 | 4.77 | CHEMBL | ||||
Receptor tyrosine-protein kinase erbB-4 | Kinase | Kd | 7.27 | CHEMBL | |||||
Serine/threonine-protein kinase 10 | Kinase | Kd | 5.59 | CHEMBL | |||||
Receptor-interacting serine/threonine-protein kinase 2 | Kinase | Kd | 5.44 | CHEMBL | |||||
STE20-like serine/threonine-protein kinase | Kinase | Kd | 5.48 | CHEMBL | |||||
Dual specificity mitogen-activated protein kinase kinase 7 | Kinase | Kd | 5.36 | CHEMBL | |||||
Receptor tyrosine-protein kinase erbB-3 | Kinase | Kd | 5.26 | CHEMBL | |||||
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta | Kinase | Kd | 6.17 | CHEMBL | |||||
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma | Kinase | Kd | 5.12 | CHEMBL | |||||
Phosphatidylinositol 4-kinase beta | Kinase | Kd | 6.03 | CHEMBL | |||||
Multidrug resistance protein 1 | Transporter | WOMBAT-PK | |||||||
Dual specificity mitogen-activated protein kinase kinase 5 | Kinase | Kd | 5.96 | CHEMBL | |||||
ATP-binding cassette sub-family G member 2 | Transporter | WOMBAT-PK | |||||||
Tubulin alpha-1A chain | Structural | Kd | 7.27 | CHEMBL |
ID | Source |
---|---|
4026029 | VUID |
N0000179782 | NUI |
D04024 | KEGG_DRUG |
388082-78-8 | SECONDARY_CAS_RN |
4026029 | VANDF |
C1506770 | UMLSCUI |
FMM | PDB_CHEM_ID |
CHEMBL554 | ChEMBL_ID |
CHEMBL1201179 | ChEMBL_ID |
D000077341 | MESH_DESCRIPTOR_UI |
DB01259 | DRUGBANK_ID |
5692 | IUPHAR_LIGAND_ID |
8378 | INN_ID |
0VUA21238F | UNII |
208908 | PUBCHEM_CID |
480167 | RXNORM |
339254 | MMSL |
d06672 | MMSL |
012020 | NDDF |
012022 | NDDF |
425466009 | SNOMEDCT_US |
425820005 | SNOMEDCT_US |
426238006 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
TYKERB | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0671 | TABLET | 250 mg | ORAL | NDA | 34 sections |
TYKERB | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0078-0671 | TABLET | 250 mg | ORAL | NDA | 34 sections |
Lapatinib | Human Prescription Drug Label | 1 | 68180-801 | TABLET | 250 mg | ORAL | ANDA | 28 sections |